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A B S T R A C T
Measuring synaptic density in vivo using positron emission tomography (PET) imaging-based biomarkers tar-
geting the synaptic vesicle protein 2A (SV2A) has received much attention recently due to its potential research
and clinical applications in synaptopathies, including neurodegenerative and psychiatric diseases. Fluid-based
biomarkers in proteinopathies have previously been suggested to provide information on pathology and disease
status that is complementary to PET-based measures, and the same can be hypothesized with respect to SV2A.
This review provides an overview of the current state of SV2A PET imaging as a biomarker of synaptic density,
the potential role of fluid-based biomarkers for SV2A, and related future perspectives.
1. Introduction
In the central nervous system, neurons communicate via neuro-
transmitters that are released into the synaptic cleft, where they bind
to, and influence, receptors on pre- and post-synaptic neurons (Alberts
et al., 1997). Critical to this process are synaptic vesicles (SV), neuro-
transmitter-containing storage units located in synaptic boutons. The
SV protein 2A (SV2A) is an integral 12-transmembrane domain glyco-
protein expressed in synaptic vesicles throughout the brain (Bartholome
et al., 2017; Mendoza-Torreblanca et al., 2013; Shi et al., 2011).
Though the exact physiological role of SV2A remains unclear, SV2A
dysfunction or decreased expression has been implicated in neurode-
generative disorders such as Alzheimer's disease (AD) (Robinson et al.,
2014) and various neurological conditions, including epilepsy (Crowder
et al., 1999; Lynch et al., 2004).
Positron emission tomography (PET) is a molecular imaging tech-
nique that can be used to quantify the density of a molecular target,
under both physiological and pathological conditions. A PET-derived
measure of brain SV2A has the potential to serve as an in vivo biomarker
of synaptic density; this would prove of value in the investigation of
synaptopathies, disorders associated with alterations in the function or
density of synapses (Robinson et al., 2014; Stampanoni Bassi et al.,
2017; Wang et al., 2017). The rationale for developing a PET tracer
targeting SV2A is two-fold: SV2A is a known target for efficient anti-
epilepsy drugs such as levetiracetam, and a PET tracer binding to SV2A
could be used to study the drug receptor occupancy in clinical devel-
opment of new drug candidates. However, due to its widespread ex-
pression in synapses throughout the brain, imaging of SV2A could also
potentially be used to assess synaptic integrity in synaptopathies such
as Alzheimer's disease (AD). While PET can provide spatial information,
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fluid-based (i.e., cerebrospinal fluid [CSF], plasma or serum) measures
could provide complementary information and carry a number of
practical advantages. In this review, we discuss the current status of
SV2A PET imaging, the potential role of fluid-based SV2A biomarkers,
and related future perspectives, including recent calls for the develop-
ment of multiparty platforms addressing synaptopathy drug discovery.
2. Basic facts about SV2A and its role in synaptic function
SV2A is expressed throughout all brain areas, apart from trigeminal
and facial nerve nuclei, and is especially abundant in subcortical areas
such as the thalamus and basal ganglia (Bajjalieh et al., 1994). The
expression of SV2B and SV2C is more restricted; SV2B is primarily ex-
pressed in the cortical regions and in the hippocampus, overlapping in
these regions with SV2A, but is absent in most subcortical regions,
whereas SV2C on the other hand is only present in the striatum, pal-
lidum, midbrain, brainstem, substantia nigra and olfactory bulb
(Bajjalieh et al., 1994; Janz and Südhof, 1999). The total number of SV2
proteins (including SV2B and C isoforms) is highly consistent across
vesicles in rat brain homogenates, with 2–5 copies per vesicle (Mutch
et al., 2011; Takamori et al., 2006). Two alternative hypotheses re-
garding the role of SV2A in exocytosis mediated by Ca2+ have been
suggested, stating that SV2A is either regulating the presynaptic Ca2+
levels during repetitive activity or functioning as a target for residual
Ca2+ (Mendoza-Torreblanca et al., 2013). Malfunctioning SV2A, in-
vestigated in knockout mice, results in presynaptic Ca2+ accumulation,
triggering abnormal neurotransmitter release, destabilizing synaptic
circuits and inducing epilepsy (Janz et al., 1999). In neuronal cell
cultures, knockdown of SV2A resulted in a 29% decrease in dendritic
spine density (Cohen et al., 2011). When the expression of SV2A was
studied during brain development in mice, a marked increase was
shown in seven days old mice. This was accompanied by myelinogen-
esis and synaptic plasticity, indicating that high levels of SV2A are re-
quired during postnatal brain development. By contrast, seven day old
SV2A knockout mice showed generalized seizures (Crèvecœur et al.,
2013a). It has also been suggested that SV2A is responsible for the
endocytosis to the SV of the SV protein synaptotagmin-1 (SYT1), and, as
such, is involved in maintaining the readily releasable pool of SVs (Yao
et al., 2010). Decreased expression of SV2A has thus been shown to
result in lowered levels of SYT1 in the SV, a finding confirmed in SV2A/
B knock-out mice, where SYT1 and the ratio of SYT1 to synaptophysin
(SYN) are markedly decreased, but no effects were seen on levels of
VAMP2/synaptobrevin or vesicular glutamate transporter 1 (Yao et al.,
2010).
3. Clinical implications of a SV2A biomarker
3.1. Epilepsy
Expression of the SV2A protein has been found to be reduced with
40% in brain tissue resected from the seizure onset zone in patients
with temporal lobe epilepsy unresponsive to pharmacological treatment
(Crèvecœur et al., 2013b; Feng et al., 2009). Levetiracetam, an anti-
epileptic drug that binds SV2A which was approved for use in the USA
in 1999 by the Food and Drug Administration (Gillard et al., 2006;
Lynch et al., 2004; Shi et al., 2011), has shown itself useful in the
management of seizures. However, the drug-target interaction, as well
as the mechanism of action, is still unclear. Further, SV2A protein ex-
pression has been shown to predict the efficacy of levetiracetam
therapy among glioma patients (de Groot et al., 2011), a population in
which seizures are experienced by between 50 and 80% of the patients.
Biomarkers for SV2A may therefore be useful, both in predicting the
outcome of pharmacological treatments and in localizing the seizure
onset zone for surgical planning.
3.2. Alzheimer's disease
AD is the most common cause of dementia (Adlard et al., 2014),
characterized neuropathologically by the abnormal accumulation of
amyloid-β plaques and formation of neurofibrillary tangles composed of
hyperphosphorylated tau, as well as synaptic- and neurodegeneration.
The amyloid-β oligomers that downstream form the amyloid-β plaques
have been identified as the species exerting the toxic effects causing
synaptic loss (Klein, 2013). Amyloid-β oligomers accumulate at ex-
citatory synapses mainly at postsynaptic terminals, but presynaptic sites
of the synapse are also affected (Pickett et al., 2016). Similarly, it is not
the neurofibrillary tangles composed of tau that are believed to cause
neurodegeneration, but soluble tau oligomers that have synaptotoxic
effects, with suggested mechanisms including overactivation of gluta-
matergic neurotransmission, calcium dysregulation and reductions of
the memory-associated protein KIBRA (Forner et al., 2017). Over-
expression of amyloid-β and tau accelerates synaptic and cognitive
impairment (Lasagna-Reeves et al., 2011; Zempel and Mandelkow,
2012).
While not specific for AD, neurodegeneration is important for the
staging of the disease and for the prediction of clinical progression
(Jack et al., 2018). PET imaging of glucose metabolism using fluorine-
18 labelled fluorodeoxyglucose ([18F]FDG) has long been used to dif-
ferentiate AD from other neurological conditions, based on its char-
acteristic pattern of decreased metabolic activity. [18F]FDG, however, is
metabolized in both neurons and glial cells (astrocytes, microglia and
oligodendroglia) and not a direct marker of synaptic loss and it is
sensitive to blood glucose levels, medication and physical and sensory
activity at the time of the PET scan. In addition, recent evidence in-
dicates that [18F]FDG PET signal, which has been used as an index of
neuronal activity, is also sensitive to astroglial metabolism (Zimmer
et al., 2017). Other imaging approaches used in the diagnosis of AD
include 99mTc-HMPAO SPECT or [15O]H2O PET, for evaluation of def-
icits in cerebral blood flow, showing similar patterns of loss as [18F]
FDG. 99mTc-HMPAO SPECT, however, suffers from limited spatial re-
solution, and the short half-life of [15O]H2O PET limits its use to centers
with access to cyclotron production (Herholz et al., 2002; Ishibashi
et al., 2015). Post mortem examination of hippocampal expression of
SV2A has shown significant loss in the outer molecular layer in patients
with AD, as compared to controls (Robinson et al., 2014). Higher loss of
SV2 has further been associated with impaired global cognition eval-
uated using the Mini-Mental State Examination (MMSE) (Robinson
et al., 2014). Achieving a better understanding of how alterations in
synaptic density in AD relate to amyloid-β and tau pathology carries
great potential for a more accurate prediction of disease progression
and the discovery of new treatment strategies.
3.3. Parkinson's disease
Parkinson's disease (PD) is the second most common progressive
neurodegenerative disease. According to the Global Burden of Disease
Study, an estimated 6.2 million people presently live with the disease, a
number that, similar to AD, is predicted to increase (GBD 2015
Neurological Disorders Collaborator Group, 2017). The pathogenesis of
PD is believed to involve the accumulation of toxic oligomeric forms of
the presynaptic neuronal protein α-synuclein. These are thought to
affect synaptic function, ultimately resulting in impaired synaptic
plasticity, altered dopaminergic neurotransmission, and the loss of
dopaminergic neurons in the striatum (Bellucci et al., 2015). These
processes precede the appearance of the motor, cognitive and olfactory
symptoms in PD by several decades, with the number of dopaminergic
neurons depleted by 50–70% by the time the clinical features appear
(Seifert and Wiener, 2013). Focusing on the regeneration of synapses
instead of the restoration of extracellular dopamine may represent a
conceptual shift in the development of new treatments for PD (Tsui and
Isacson, 2011). As such, biomarkers for synaptic density may be of
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value both in the early diagnosis of PD and in the tracking of its pro-
gression, but also as a means to accelerate the development of novel
disease-modifying interventions.
3.4. Other neuropsychiatric disorders
The SV2A-targeting antiepilepsy drug levetiracetam has also been
proposed to be useful as a neuroprotective drug in the treatment of
other neurological disorders, such as management of seizures following
stroke and traumatic brain injury (Shetty, 2013), reducing chorea in
Huntington's disease – demonstrating a decrease in the chorea subscore
on the Unified Huntington Disease Rating Scale (Zesiewicz et al., 2006),
reducing anxiety and mania in various psychiatric disorders (Farooq
et al., 2009) a potential use in management of tics in Tourette's syn-
drome in a subpopulation of the patients (Martínez-Granero et al.,
2010) and significantly reduced abnormal movements in tardive dys-
kinesia (Woods et al., 2008). Though clinically diverse, these conditions
all involve synaptic alterations; the monitoring of synaptic density may
thus both provide insight into the pathogenesis of these disorders as
well as prove useful in the prediction of treatment efficacy and ther-
apeutic response monitoring.
4. Current state of imaging biomarkers
The development and application of SV2A PET tracers has the po-
tential to significantly improve the understanding of the function and
role of the protein such as providing critical information on the SV2A
target engagement of antiepileptic drugs in clinical development, and
enable the characterization of the distribution and expression of SV2A
in epileptic patients. Further applications include clinical diagnosis of
e.g. AD, monitoring of drugs targeting synaptic function and increased
understanding of the role of synaptic degeneration in brain disorders. A
PET ligand targeting SV2A would provide an estimate of the protein
density, which would be assumed to reflect the overall synaptic density
in a brain region. It is however not clear, yet, to which degree this
measurement is affected by SV2A dysfunction, changes in expression
within the vesicles or the number of vesicles within the synapse and the
overlap and differences of such processes in different neurological
disorders. There are also findings indicating that while SV2A is ex-
pressed throughout almost the entire brain, the levels vary between
regions (Bajjalieh et al., 1994).
Given the proven clinical efficacy and affinity to SV2A of levetir-
acetam (Lynch et al., 2004), it is noteworthy that [11C]levetiracetam
and a structurally diverting analogue labelled with technetium-99m
have been synthesized for potential use in PET and single photon
emission tomography (SPECT), respectively (Cai et al., 2014; Rashed
et al., 2018). In vivo evaluation has not yet been reported for these
candidate tracers, but the affinity to SV2A (Ki= 1.6 μM for structurally
unmodified levetiracetam) is likely too low for optimal in vivo imaging
(Gillard et al., 2006). Generally speaking, the usefulness of a compound
as a PET ligand depends on its selectivity to the biological target
(ranging from 30-fold to> 100-fold), its affinity to the target (Kd)
(usually in the low nM range) but also the relationship between affinity
and density of the target (Bmax/Kd≥10) (Andrés and Schmidt, 2017;
Honer et al., 2014; Mathis et al., 2017). Low Kd reflects a high asso-
ciation rate and relatively slow dissociation rates of the ligand-target
binding, which is needed for use with radionuclides with short half-
lives. The high affinity, however, is also important in order to distin-
guish the specific from non-specific binding, one of the greatest im-
pediments of PET imaging of the central nervous system. Moderate li-
pophilicity (logD=1–3), relatively low molecular weight (> 700 Da)
and the ability of parent compound – but not radiolabelled metabolites
– to cross the blood-brain barrier are other important properties of a
successful PET ligand (Mathis et al., 2017).
Concurrently, UCB Pharma (Braine-l'Alleud, Belgium) initiated a
research program with the purpose of better understanding the role and
function of SV2A, and to identify high affinity ligands with suitable
properties for development as SV2A PET ligands (Mercier et al., 2014).
Mercier and colleagues presented a selection of their> 500 compounds
tested for SV2A potency (Mercier et al., 2014): three compounds, UCB-
A, UCB-H and UCB-J, were outlined as lead compounds based on their
pharmacological and labelling properties and not the least if amenable
for labelling.
4.1. Preclinical validation
The three lead compounds identified by UCB Pharma were further
developed in cooperation with three sites: the [11C]UCB-A compound
was studied in Uppsala, Sweden, [18F]UCB-H in Liège, Belgium, and
UCB-J, labelled both with carbon-11 and fluorine-18, at Yale
University, New Haven, USA.
In Uppsala, [11C]UCB-A was produced in 3–5 GBq quantities ready
for injection via a two-step synthesis route including 11C-methylation
and deprotection (Estrada et al., 2016). Frozen section auto-
radiography, biodistribution and dosimetry, and a study of in vivo tracer
binding with competing compounds for displacement studies were all
performed in Sprague-Dawley rats to study the characteristics of [11C]
UCB-A (Estrada et al., 2016). The in vitro studies showed that binding of
[11C]UCB-A was blocked in a dose dependent manner by administration
of the reference SV2A ligands levetiracetam and seletracetam, with IC50
values of 0.78 and 0.14 μM, respectively. Further dynamic PET scan-
ning was performed in six pigs, including blocking studies and meta-
bolite analysis. The PET binding studies also confirmed the ability to
block or displace [11C]UCB-A uptake with reference compounds in both
species, and the baseline studies demonstrated a rather slow accumu-
lation and washout, where tmax had not been reached at 90min when
the PET scan ended. The metabolite analysis in pigs demonstrated a
slow metabolism with 77 ± 3% of tracer still intact at 75min post
injection. Tracer kinetics were best described by a one-tissue com-
partment (1-TC) model at baseline and a two-tissue compartment model
(2-TC) after blocking (Estrada et al., 2016). The biodistribution and
dosimetry studies indicated that [11C]UCB-A distributed rapidly from
blood to organs, with the highest uptake in adrenals and brain, and
showed that the effective doses were 2.9 μSv/MBq in male rats and
4.9 μSv/MBq in female rats, allowing for up to 5 administrations of
400MBq in humans (Estrada et al., 2016).
[18F]UCB-H has been synthesized within 150min and obtained in
30% radiochemical yield by a four-step synthesis route involving nu-
cleophilic 18F-fluorination of the pyridine precursor, reductive amina-
tion and ring closure (Warnock et al., 2014). In the preclinical work on
[18F]UCB-H, the affinity to human and rat SV2A was studied in both
recombinant and native tissues using binding competition, demon-
strating an IC50 of 40 nM for recombinant human SV2A and similar in
native tissue (Warnock et al., 2014). In vivo properties were studied in
Sprague-Dawley rats, including a test-retest study. [18F]UCB-H ex-
hibited a rapid uptake phase, reaching peak uptake (tmax) around 5min
post injection, followed by a fast wash-out phase and faster metabolism
than for [11C]UCB-A in pigs, with< 20% intact tracer remaining after
60min as measured with HPLC (Warnock et al., 2014). Brain content of
the parent compound and metabolites were also studied in rats,
showing that> 90% of the brain radioactivity was related to the parent
compound at 20min post injection (Becker et al., 2017). Brain uptake
of [18F]UCB-H can reliably be quantified using Logan graphic analysis
as well as by using population-based input functions, and a test-retest
reproducibility of around 10% was found for the whole-brain VT
(Becker et al., 2017; Warnock et al., 2014). It has further been shown
that the chirality of [18F]UCB-H has a significant impact on SV2A af-
finity, and that the (R)-enantiomer has a 10-fold higher affinity than the
(S)-enantiomer, but that it has no impact on the uptake pattern (Becker
et al., 2017). Preliminary data of [18F]UCB-H in rhesus and cynomolgus
nonhuman primates confirmed a higher signal of the (R)-enantiomer
compared to the racemate (Carroll et al., 2018). Preclinical dosimetry
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studies of [18F]UCB-H were performed in male mice, indicating an ef-
fective dose of 18.8 μSv/MBq, rendering it suitable for a single ad-
ministration of 325MBq (Bretin et al., 2013).
[11C]UCB-J was synthesized in 11% radiochemical yield by palla-
dium-mediated cross-coupling of a pyridine-trifluoroborate precursor
with [11C]methyl iodide (Nabulsi et al., 2016). The tmax of [11C]UCB-J
in rats occurred 5min post injection, with rapid equilibration with
plasma and only very low levels of two of the three metabolites found in
brain tissue (Nabulsi et al., 2016). In vitro binding studies of [11C]UCB-J
showed an SV2A affinity of 7 nM, 10-fold higher than the affinity to
SV2C, and 100-fold higher than SV2B affinity (Nabulsi et al., 2016).
Nonhuman primate studies have been performed for [11C]UCB-J in
both rhesus monkeys and in a baboon (Finnema et al., 2016; Nabulsi
et al., 2016). The rhesus monkey studies demonstrated the ability to
block [11C]UCB-J binding using levetiracetam. Tmax was reached
5–8min post injection in the cortical regions, with around 25% of the
parent compound intact after 90min. White matter uptake, represented
by the centrum semiovale, was significantly lower than the cortical
uptake. Tracer kinetics both in rhesus monkeys and the baboon were
best described using a 1-TC model, similarly to [11C]UCB-A (Finnema
et al., 2016; Nabulsi et al., 2016). Correlations between regional in vivo
SV2A signal, defined as [11C]UCB-J VT, and in vitro measurement in-
vestigated in the baboon euthanatized after the scan, showed high
correlations across grey and white matter regions (R2=0.72) though a
more moderate association was found when only including grey matter
regions (R2=0.31) (Finnema et al., 2016). In the same tissues, in vitro
tissue analysis using optical density by Western blot showed a high
correlation between SV2A and synaptophysin (SYN), the “gold stan-
dard” marker of synaptic density. Both SV2A and SYN signals were
absent or weak in the centrum semiovale (Finnema et al., 2016). Do-
simetry studies were also performed in rhesus monkeys, demonstrating
an effective dose of 4.5 μSv/MBq for [11C]UCB-J, comparable to that of
[11C]UCB-A (Nabulsi et al., 2016).
The successful synthesis of single enantiomer [18F]UCB-J has briefly
been described and involved preparation from an organoiodonium salt
or ylide precursor under conditions for nucleophilic substitution with
[18F]fluoride (Li et al., 2017). As expected, [18F]UCB-J displayed si-
milar imaging properties as [11C]UCB-J. Preclinical work to develop a
fluorine-18 labelled SV2A ligand has also been performed by Invicro.
The synthesis of [18F]MNI-944 (racemate of [18F]UCB-J) was not re-
producible and the investigations continued with difluoro-substituted
derivates of UCB-J that were less challenging to label. [18F]MNI-1038
(racemate), [18F]MNI-1126 ((R)-enantiomer) and [18F]MNI-1128 ((S)-
enantiomer) were compared to [18F]MNI-944, [18F]UCB-H ([18F]MNI-
942) and [18F]MNI-1080 (racemate of [18F]UCB-H), in rhesus and cy-
nomolgus monkeys (Constantinescu et al., 2018). [18F]MNI-1126 was
identified as the best candidate based on its favorable kinetic proper-
ties: tracer kinetics was best described by 1-TC, tmax was reached at
around 7min post injection in pons and cerebellar lobes and 50min in
anterior cingulate and cortical structures, VT in grey matter was around
25–30mL/cm3 and sensitive to blocking with levetiracetam, whereas
the VT in centrum semiovale was approximately 80% lower and less
impacted by pre-blocking (Constantinescu et al., 2018). After 60min,
27% of the injected tracer was still intact.
Independently from the work performed by Invicro, Yale has also
pursued studies of fluorine-18-labelled derivatives of UCB-J, [18F]SDM-
2 (Cai et al., 2017) and [18F]SDM-8 (Li et al., 2018), the latter identical
to [18F]MNI-1126. In preclinical evaluation in non-human primates,
these compounds exhibited high brain uptake, fast kinetics, and high
specific binding in brain.
Fig. 1 shows the chemical structures of selected SV2A PET ligands.
4.2. Clinical validation
Preliminary data on the clinical validation of [11C]UCB-A in six
epilepsy patients and two healthy controls has confirmed the slow
kinetics of the tracer in a PET-MR study performed with arterial blood
sampling (Lubberink et al., 2017). While a reversible 2-TC model best
described the data, the model failed to provide robust estimates of VT
and BPND. The peak activity in brain was reached 70–80min post in-
jection, and centrum semiovale was demonstrated to be a useful re-
ference region for quantification of uptake together with Logan graphic
analysis. The metabolite analysis indicated a rather slow metabolism of
UCB-A, although faster than previously shown in pigs, with 50% of the
parent compound intact after 90min (Lubberink et al., 2017). The
average grey matter VT was 24mL/cm3 compared to 3.2mL/cm3 in
centrum semiovale, indicating a high dynamic range. Initial results
show a considerable reduction in cortical VT after blocking with leve-
tiracetam (unpublished data).
The effective dose of [18F]UCB-H in humans was 15.4 μSv/MBq,
similar to the preclinical estimate of 18.8 μSv/MBq, and in the normal
range for fluorine-18-labelled PET tracers, with the urinary bladder
wall, the gallbladder wall and the liver receiving the highest dose
(Bretin et al., 2015, 2013). Tmax within the brain was reached at
5–10min post injection, followed by a fast wash-out phase in a cohort
of two younger and two older healthy controls (Bahri et al., 2017). After
90min, an average of 17% of the intact tracer remained. The 2-TC
model described the experimental data best, but similar to [11C]UCB-A,
Logan was found to provide more robust estimates of VT values, ranging
from 4.3mL/cm3 in the centrum semiovale to around 8mL/cm3 in
putamen (Bahri et al., 2017). BPND estimates were derived from dis-
tribution volume ratio using the centrum semiovale; the BPND was
overall found to be higher in older controls, however, likely due to a
slightly higher VT in the white matter of younger subjects.
The most extensive clinical validation of the SV2A tracers has been
performed using [11C]UCB-J (Finnema et al., 2017, 2016). Investigated
in 10 young healthy controls and three patients with epilepsy, [11C]
UCB-J exhibited favorable kinetic properties, with a tmax around
10–25min post injection, followed by a rapid wash-out phase. Kinetics
were well described by a 1- or 2-TC model, and reliable measurements
of the BPND could be produced using the simplified reference tissue
model (Finnema et al., 2017, 2016). VT ranged from 5.2mL/cm3 in the
centrum semiovale to 22.5 mL/cm3 in the putamen, indicating a wider
dynamic range than for [18F]UCB-H. Levetiracetam was shown to dis-
place [11C]UCB-J binding substantially in cortical regions, but with less
effect on the uptake in centrum semiovale, confirming both the speci-
ficity of cortical [11C]UCB-J uptake, and the mainly non-specific nature
of the uptake in white matter. The test-retest reproducibility of [11C]
UCB-J was investigated in five healthy controls, showing a mean
variability of 3–9% across regions (Finnema et al., 2017). The re-
maining fraction of intact tracer was around 30% 90min post injection.
Fig. 2 shows representative parametric VT images of [11C]UCB-A,
[18F]UCB-H and [11C]UCB-J in healthy controls.
4.3. Clinical research
Given the novelty of SV2A PET imaging, available data from clinical
research are still limited. However, preliminary data from several stu-
dies have recently been reported at scientific conferences.
In order to investigate the potential of SV2A PET imaging as a
biomarker for neurodegeneration in AD, dynamic [11C]UCB-J scans
were performed in 10 amyloid-β positive patients with amnestic mild
cognitive impairment (MCI) or mild AD and 11 age-matched amyloid-β
negative healthy controls, with successful arterial plasma sampling
performed on nine patients and eight healthy controls (Chen et al.,
2018). Parametric images showing VT and the influx rate constant K1,
proportional to blood flow, were created using the 1-TC model. In ad-
dition, the simplified reference tissue model was used to estimate re-
gional BPND using the centrum semiovale as reference region, alle-
viating the need for arterial plasma sampling. Significantly lower [11C]
UCB-J uptake (VT) and binding (BPND) was found in the hippocampus of
patients. No difference was however seen in the VT of the centrum
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semiovale, supporting the use of this region as a reference region for
[11C]UCB-J PET imaging (Chen et al., 2018). Preliminary data have
shown an age dependent reduction in VT in both subcortical structures
and centrum semiovale, however, these findings may be due to differ-
ences in free fraction or partial volume effects (Carson et al., 2018).
Compared to the typical pattern of hypometabolism seen in AD
using [18F]FDG, the spatial extent of decreases in [11C]UCB-J uptake
were significantly more confined. The reduction in hippocampal
binding is in line with the early loss of entorhinal cortical cell projec-
tions to the hippocampus, and reductions of hippocampal SV2A seen in
post mortem studies in AD brain tissue (Braak et al., 2011; Robinson
et al., 2014). Similar findings have also been reported for [18F]UCB-H in
AD, where a significant decrease in synaptic density was reported in
medial temporal structures, centered on the entorhinal cortex and ex-
tending to the amygdala and basal forebrain (Salmon et al., 2017). The
pattern of [11C]UCB-J K1 images, assumed to represent cerebral blood
flow, were more similar to typical [18F]FDG patterns seen in AD. In-
deed, images showing parameters related to blood flow have previously
been suggested as an alternative to [18F]FDG metabolic imaging (Chen
et al., 2015; Hsiao et al., 2012; Rodriguez-Vieitez et al., 2016). This
suggests that SV2A PET imaging could provide information on two
distinct processes, i.e., synaptic density and cerebral blood flow, de-
pending on arterial blood sampling or the use of a valid reference re-
gion (Chen et al., 2018).
[11C]UCB-J binding has also been shown to be decreased in the
seizure onset zone of temporal lobe epilepsy patients, with asymmetry
indices ranging from around 40–65% in the hippocampus (Finnema
et al., 2016). Further, preliminary data from studies using [11C]UCB-J
have shown decreased SV2A binding in patients with major depressive
disorder (Holmes et al., 2018) and reductions of SV2A binding in the
Fig. 1. Selection of labelled compounds developed for SV2A receptor imaging with PET.
Fig. 2. Typical volume of distribution (VT) images of (A) [11C]UCB-A, (B) [18F]UCB-H, and (C) [11C]UCB-J in healthy controls. The [11C]UCB-J image, acquired on a
high-resolution research scanner, was post-smoothed with a 4mm Gaussian filter to obtain similar spatial resolution as the other two images. Note the difference
limits on the color scales. [18F]UCB-H, and [11C]UCB-J images are courtesy of Drs. Christine Bastin and Eric Salmon, University of Liége, and Drs. Mika Naganawa
and Richard Carson, Yale University PET Center.
K. Heurling, et al. Molecular and Cellular Neuroscience xxx (xxxx) xxx–xxx
5
substantia nigra and other parts of the brain in a small cohort of PD
patients (Matuskey et al., 2018).
The usefulness of [11C]UCB-J in drug development was recently
demonstrated in a drug receptor occupancy study of the investigational
new epilepsy drug padsevonil in healthy controls (Koole et al., 2018).
This study also validated the centrum semiovale as reference region and
standardized uptake ratios (SUVR) as a semi-quantitative approach,
concluding that a SUVR estimated over 60–90min post injection pro-
vides an accurate estimate of the tracer binding (Koole et al., 2018).
It remains unclear what increased or decreased SV2A-ligand binding
represents in the living brain and if the signal reflects similar processes
in neurodegenerative and psychiatric diseases and if the method is
sensitive enough to detect early changes, or if it will only be valuable in
later stages of the disease progression. Future research should examine
if reduced SV2A-binding represents synapse loss, reduced protein ex-
pression in inactive neurons or neurons about to degenerate or if it is
actively degraded by proteases.
5. Current state of fluid biomarkers for neuronal loss
Bodily fluids such as cerebrospinal fluid (CSF) and plasma are
considered to be important sources for biomarkers reflecting neurode-
generation. Although PET carries the advantage of providing topo-
graphical information, there is little doubt that an accessible fluid
biomarker would be preferable in a diagnostic setting, for participant
screening or repeated sampling in clinical trials. CSF is the superior
source for fluid biomarker development given its direct contact with the
extracellular space of the brain where biochemical changes of relevance
to neuronal health should be reflected. Advances in the last decade have
proven that “core” CSF biomarkers can accurately reflect key elements
of disease and contribute substantially to a diagnostic conclusion, even
at the preclinical phase (e.g., Aβ1–42, P-tau and T-tau for AD) (Blennow
and Zetterberg, 2018).
Despite the CSF biomarkers now being apart of the research diag-
nostic criteria for AD (Dubois et al., 2014), the degree of synaptic de-
generation might be a better predictor of cognitive decline than amy-
loid or tau pathology (Blennow et al., 1996). Moreover, given the
dynamic plasticity of the synapse, a fluid biomarker of its function
would be a more useful tool in monitoring of disease modifying
therapies, functioning as a “state” biomarker for the intensity of sy-
naptic degeneration or damage, in contrast to “stage” biomarkers that
measure the stage of the accumulated synaptic loss, see also (Blennow
and Hampel, 2003).
Early non-targeted proteomics highlighted candidate proteins in-
volved in mechanisms at the pre- and post-synaptic terminals. However,
at that time, there was no robust biomarker for synaptic dysfunction.
CSF concentrations of the pre-synaptic proteins synaptosomal-asso-
ciated protein 12 (SNAP-25) and SYT1 have been shown to be sig-
nificantly increased in established and pre-clinical AD (Brinkmalm
et al., 2014; Öhrfelt et al., 2016; Zhang et al., 2018). This is thought to
reflect the substantial synaptic degeneration and loss in AD (Masliah
et al., 2001). Indeed, the levels of both SNAP-25 and SYT1 are reduced
in cortical areas of post mortem tissue of pathologically confirmed AD
cases (Brinkmalm et al., 2014).
The dendritic protein neurogranin (Ng) is the most evaluated sy-
napse-related protein measured in neurodegeneration. After developing
novel monoclonal antibodies to measure neurogranin by enzyme-
Linked immunosorbent assays (ELISA), increased levels of Ng have been
reported in several studies (Hellwig et al., 2015; Kvartsberg et al., 2015;
Portelius et al., 2015) but surprisingly, this observation seems to be
specific for AD and not for other neurodegenerative diseases
(Wellington et al., 2016), a finding replicated in a large cohort of pa-
tients with different neurodegenerative diseases (Portelius et al., 2018).
The increases of CSF alpha-synuclein in AD and Creutzfeldt-Jakob dis-
ease (Hall et al., 2012; Oeckl et al., 2016), and correlation with CSF tau
suggests the potential role of CSF α-synuclein as a biomarker for
synapse dysfunction (Magdalinou et al., 2015). In contrast, CSF α-sy-
nuclein seems to be decreased in synucleinopathies such as Parkinson's
disease and dementia with Lewy bodies (Parnetti et al., 2011; Tokuda
et al., 2006).
Being the main focus of this review, SV2A peptides, predominantly
from the lumen domain, have been detected in CSF using in-depth ex-
plorative proteomics (Schutzer et al., 2010). Despite this, there is cur-
rently no validated immunoassay for the detection of SV2A in bodily
fluids. A blood biomarker reflecting central nervous system SV2A is
unlikely given the substantial expression from pancreas (The Human
Protein Atlas, 2018). As previously stated, post mortem tissue studies
have also demonstrated decreased expression of SV2A in AD compared
to controls (Robinson et al., 2014). One might hypothesize that con-
centrations of CSF SV2A may act in the same manner as the majority of
synaptic proteins and increase in diseases with extensive neuronal loss.
However, synaptic proteins with similar postulated functions as SV2A
have been shown to decrease in AD compared to healthy controls (Duits
et al., 2018; Simonsen et al., 2008). Contactin-2, a soluble cell-adhesion
protein located on synaptic membranes, are also decreased in AD post
mortem brain and CSF (Chatterjee et al., 2018). Indeed, our preliminary
investigations into SV2A seem to also suggest that this is in fact the
case. Unexpectedly, these protein groups (involved in vesicular trans-
port and synaptic stability) are markedly elevated at the MCI stage of
the disease potentially reflecting early events in the pathophysiological
cascade (Duits et al., 2018). These results are promising and suggest
that this class of molecules should be explored further as potential
biomarkers for synaptic degeneration in AD and other neurodegenera-
tive diseases. Similar to SV2A imaging, we currently do not know ex-
actly what a change in the concentration of a synapse-derived molecule
in a biofluid means (altered release or secretion of the molecule into the
fluid because of synapse loss, increased or decreased synaptic activity,
or altered clearance).
6. Discussion and future prospects
The recently announced Innovative Medicines Initiative call fo-
cusing on synaptopathy drug discovery emphasizes the current view in
the field of the importance of developing reliable biomarkers for sy-
naptic deficits. Highlighting the need to “demonstrate the value of these
new tools and methods for supporting drug discovery and development
efforts across a spectrum of therapeutic CNS indications, including
neurodegenerative, neurodevelopmental and psychiatric disorders,” the
anticipated impact of this initiative is to identify and validate phar-
macologically tractable targets following an improved understanding of
how synaptic dysfunction contributes to these varied disorders
(European Commission, 2018). Early discussions surrounding the utility
of SV2A PET revolved around its potential use as a reliable marker of
neurodegeneration in AD, less sensitive to confounding factors as
compared with [18F]FDG, a widely used measure assumed to largely
reflect synaptic loss. Preliminary findings using [11C]UCB-J in a small
cohort of AD patients, however, showed a pattern of decreased activity
much less pronounced as compared to [18F]FDG (Chen et al., 2018). At
this point, it is still too early to draw any conclusions as to whether the
two in fact images very different pathologic processes. It is clear,
however, that there are many potential insights into the pathogenesis of
AD to be made with a suitable PET biomarker for SV2A at hand.
In order to achieve a wider use of PET based biomarkers for SV2A,
two main points need to be addressed: development of a fluorine-18-
labelled ligand with optimal kinetic properties, and the validation of a
simplified method of quantification. The short half-life of carbon-11 is
not a limitation at this stage, as the usefulness of the ligand is still under
investigation at centers with the necessary infrastructure and expertise.
Should SV2A ligands, however, live up to the initial hopes of being a
more reliable biomarker for neurodegeneration than [18F]FDG, carbon-
11 limits use to imaging facilities with on-site production. For SV2A
ligands to replace [18F]FDG in clinical applications further down the
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road, fluorine-18 labelled ligands would be the most feasible option.
For the currently most promising and most used ligand, [11C]UCB-J,
there are some concerns regarding the validation of an ideal brain re-
ference region completely unaffected by displacement, and the under-
lying reason for the demonstrated reduced binding in the centrum
semiovale with age must be clarified as it may complicate use in
longitudinal studies (Carson et al., 2018). To date though, the centrum
semiovale is still the most favorable alternative and it is likely suitable
for use as a reference region in cross-sectional studies. In this early
stage, PET imaging using [11C]UCB-J should ideally be performed both
using dynamic scanning and arterial blood sampling, which results in
an experimental setup demanding for both patients and imaging sites.
While specific CSF composition and detection of SV2A are still under
investigation, other synaptic measures have shown value as state
markers in disease progression, and may, analogous to the case of PET
and CSF based biomarkers for amyloid-β and tau, provide com-
plementary understanding of the etiology and potential treatments
strategies of synaptopathies.
6.1. SV2A imaging: a sunrise of good fortune or a false dawn?
While the optimal PET tracer for targeting SV2A may still be under
development, some questions remain in terms of the usefulness of SV2A
as a proxy for synaptic density and for tracking synaptic loss. The
density of SV2 isoforms has been shown to be consistent across the
brain of rats, however, the expression of SV2A seems to vary across
regions. Further, in addition to the aforementioned age-dependent de-
crease in SV2A density (as measured by [11C]UCB-J), it is not known
whether a decrease in SV2A binding strictly reflects neuronal loss, as it
could also represent decreased density of SV2A in vesicles, dysfunc-
tional SV2A or a decreased number of vesicles. Conversely, it is also not
known whether a damaged neuron could in fact remain to contain the
same density of SV2A proteins. Before these aspects have been eluci-
dated, the relevance of SV2A as a biomarker of synaptopathies remains
to be demonstrated.
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